South Africa officially launched the rollout of Lenacapavir, a long-acting HIV prevention drug, in Secunda, Mpumalanga, on June 5, 2026. This significant event was marked by the formal introduction of the medication by President Cyril Ramaphosa, showing the government's commitment to combating HIV. Prof Nicholas Crisp, a prominent figure in public health, stated that Lenacapavir marks a significant advancement in global health. He added, "Lenacapavir is a gamechanger in the field of global health, signifying a shift from HIV prevention that requires a daily routine to a long-acting and highly effective form of protection." This new approach is anticipated to revolutionize how HIV prevention is managed in high-burdened regions.
Rollout Details and Targets
Lenacapavir is administered via an injection only twice a year, offering a remarkably less frequent dosing schedule compared to daily regimens for HIV prevention. This biennial administration is expected to significantly improve adherence and uptake among target populations. The initial phase of its rollout targets approximately 360 public clinics and health facilities across the country. These facilities are strategically situated in high-burdened districts across six of South Africa's provinces, focusing resources where the need is most critical to maximize impact.
The South African government has established specific, ambitious targets for the drug's distribution and uptake. An immediate goal is to reach one million people by the end of 2027, demonstrating a rapid deployment strategy. Looking further ahead, the government aims to expand coverage to three million individuals within three years of the rollout's commencement. This phased approach seeks to integrate the new prevention method into existing public health infrastructure while progressively broadening its reach across the country's population, ensuring equitable access to this innovative treatment. The successful implementation of these targets is key for reducing new HIV infections nationwide.
Context of HIV in South Africa
South Africa continues to face a significant challenge regarding HIV, with a substantial portion of its population affected by the epidemic. In 2025, an estimated 8.15 million people were living with HIV across the country. This figure represents approximately 12.9% of South Africa's total population, noting the widespread nature of the virus. The prevalence is notably higher within specific demographic groups, indicating areas of acute vulnerability. Among adults aged 15 to 49, the HIV prevalence rate stands at about 18.1%. These statistics show the critical need for effective prevention strategies and interventions within the nation's public health framework, making the introduction of Lenacapavir particularly timely and impactful. The long-acting nature of Lenacapavir is expected to address some of the adherence challenges faced with daily oral pre-exposure prophylaxis (PrEP).
Future Manufacturing Aspirations
South Africa has formally applied for inclusion among the African countries that will be granted rights to manufacture Lenacapavir. This initiative aligns with the country's broader goal to enhance local pharmaceutical production capabilities and foster self-reliance in healthcare. Securing manufacturing rights for the long-acting HIV prevention drug would allow South Africa to produce the medication domestically, potentially reducing costs and improving supply chain stability. This strategic move signifies a concerted effort to bolster public health infrastructure through self-sufficiency in critical drug production. This application is a key step towards ensuring broader access to Lenacapavir across the continent, particularly in regions with high HIV prevalence where local production can dramatically improve availability and affordability.
A New Era in Prevention
Lenacapavir is expected to support the government's efforts to reduce and ultimately prevent new HIV infections in South Africa, advancing the country's goal of achieving zero new HIV infections and ending AIDS as a public health threat by 2030. President Cyril Ramaphosa announced in his 2026 State of the Nation Address that the government is committed to strengthening the country's HIV treatment program through the rollout of Lenacapavir. This commitment reflects a strategic shift towards more effective and sustainable prevention methods, offering a new beacon of hope in the fight against HIV/AIDS.
